Physician profile
Andrew I Sable
NPI 1548293376
$17,562.35
in general payments reported to CMS, 2019-2025
44 companies · $3,355 in 2025
The $3,355 reported for 2025 was more than what 88% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,201 · 2020: $1,784 · 2021: $2,287 · 2022: $2,631 · 2023: $2,855 · 2024: $2,450 · 2025: $3,355.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,575 · Education: $84.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,574.73 |
| Education | $84.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,540.01 | 2019-2025 | Rinvoq, Skyrizi, Linzess |
| Janssen Biotech, INC. | $2,447.06 | 2019-2025 | Tremfya, Stelara |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,852.27 | 2019-2024 | Xifaxan, Trulance |
| Qol Medical, LLC | $1,483.43 | 2019-2025 | Sucraid, Sucraid |
| Takeda Pharmaceuticals U.S.A., INC. | $851.53 | 2019-2025 | Entyvio, Gattex, Eohilia |
| Genzyme Corporation | $788.24 | 2022-2025 | |
| Ironwood Pharmaceuticals, INC | $613.48 | 2019-2024 | Linzess |
| Celgene Corporation | $597.96 | 2021-2023 | Zeposia |
| Gilead Sciences, INC. | $551.00 | 2019-2024 | |
| Regeneron Healthcare Solutions, INC. | $546.25 | 2022-2025 | Dupixent |
| Ardelyx, INC. | $516.57 | 2022-2025 | Ibsrela |
| Redhill Biopharma INC. | $432.50 | 2020-2024 | Talicia, Aemcolo, Movantik |
| Intercept Pharmaceuticals, INC. | $374.25 | 2019-2025 | Ocaliva |
| Ferring Pharmaceuticals INC. | $345.52 | 2019-2023 | Rebyota |
| Daiichi Sankyo INC. | $334.13 | 2019-2023 | Injectafer |
Show all 44 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Aimmune Therapeutics, INC. | $316.99 | 2024-2025 | Zenpep |
| Celltrion USA INC. | $310.41 | 2024-2025 | Vegzelma |
| Nestle Healthcare Nutrition INC. | $244.89 | 2020-2023 | |
| Ipsen Biopharmaceuticals, INC | $236.16 | 2024-2025 | Iqirvo |
| Madrigal Pharmaceuticals | $215.87 | 2024-2025 | Rezdiffra, Resmetirom |
| Allergan, INC. | $197.23 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $171.97 | 2019-2024 | Dificid |
| Braintree Laboratories, INC. | $165.11 | 2019-2024 | Sutab, Suflave |
| Boston Scientific Corporation | $148.05 | 2023 | Exalt Model D |
| Medtronic, INC. | $147.92 | 2025 | Pillcam |
| Vivus LLC | $126.23 | 2021-2024 | Qsymia, Pancreaze |
| Alfasigma USA, INC. | $120.35 | 2020-2022 | |
| Evoke Pharma, INC. | $110.79 | 2021-2025 | Gimoti |
| Pentax of America, INC. | $104.26 | 2020-2021 | |
| Lilly USA, LLC | $101.55 | 2024-2025 | Omvoh |
| Novo Nordisk INC | $83.58 | 2025 | Wegovy |
| Mallinckrodt Hospital Products INC. | $68.61 | 2024-2025 | Terlivaz |
| Amgen INC. | $67.06 | 2020-2023 | Avsola |
| Phathom Pharmaceuticals, INC. | $65.33 | 2024-2025 | Voquezna |
| Romark Laboratories, Lc | $49.81 | 2020 | |
| Janssen Scientific Affairs, LLC | $44.10 | 2021 | |
| Pfizer INC. | $38.34 | 2024-2025 | |
| Cumberland Pharmaceuticals, INC. | $35.00 | 2020-2021 | |
| Exact Sciences Corporation | $30.31 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Alnylam Pharmaceuticals INC. | $25.53 | 2022 | |
| Pharmacosmos Therapeutics INC. | $18.22 | 2023 | Monoferric |
| Ucb, INC. | $14.97 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $14.81 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $14.70 | 2023 | Zeposia |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Andrew Sable listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.